Clinical outcome in patients with small intestinal non-Hodgkin lymphoma

Abstract

The clinical features and outcome of small intestinal lymphoma remain unclear. We retrospectively analyzed 23 patients who had non-Hodgkin lymphoma with a small intestinal lesion. With a median follow-up of 37 months, the 5-year overall survival and failure-free survival (FFS) were 64% and 60%, respectively. In a univariate analysis, a worse performance status at the start of treatment and the occurrence of abdominal symptoms or perforation during treatment were associated with poor survival. Perforation often resulted in a dismal prognosis in patients with uncontrollable lymphoma, but not in patients with lymphoma in remission. The role of surgery in small intestinal lymphoma remains equivocal. In the current study, surgery before other therapies favorably influenced FFS, and all patients who underwent complete resection of the small intestinal lesion had extremely favorable results. Further studies are warranted to establish optimal therapeutic strategies.

Surgical resection combined with chemotherapy can help achieve better outcomes in patients with primary colonic lymphoma

“…The GI tract is the most common site of extranodal involvement in cases of non-Hodgkin's lymphoma (NHL), with an average incidence of 5-40% [1]. The stomach is the most common site of GI lymphoma (14-38%), followed by the small intestine [2,3]. NHL in the colorectal area, however, constitutes about 10-20% of all extranodal GI tract involvement [4,5].…”

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone

“…[1][2][3] Considerable information on primary gastric DLBCL is available, but there are insufficient data on the clinical features and outcomes of primary intestinal DLBCL because it is usually studied as a subgroup of GI lymphomas. 1,[3][4][5] Although a few reports focusing on primary intestinal DLBCL have been published, [6][7][8][9] the sample sizes were small, and the optimal treatment strategies specific for primary intestinal DLBCL have not been established. Various treatment approaches have been tried, such as systemic chemotherapy similar to that used to treat nodal DLBCL and primary surgical resection of intestinal lesions and postoperative chemotherapy.…”

Bowel perforation in intestinal lymphoma: incidence and clinical features

“…Although unusual, the occurrence of perforations is potentially life threatening and leads to considerable morbidity from sepsis, multi-organ failure, prolonged hospitalization, complications of wound healing, delays in the initiation of chemotherapy and mortality. Several studies have reported an inferior outcome of GI lymphomas when complicated by perforation [2,4,5].…”